Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8GlobeNewsWire • 07/28/22
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ETGlobeNewsWire • 07/27/22
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-ReactiveGlobeNewsWire • 07/20/22
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022GlobeNewsWire • 07/14/22
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ETGlobeNewsWire • 07/01/22
Vaxart Announces Agreement with hVIVO to Develop World's First Human Omicron Challenge ModelGlobeNewsWire • 06/30/22
New Preclinical Data Demonstrate Two of Vaxart's COVID-19 Vaccine Candidates Protect Against OmicronGlobeNewsWire • 06/03/22
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly AdultsGlobeNewsWire • 06/02/22
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 TransmissionGlobeNewsWire • 05/19/22
These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall StreetThe Motley Fool • 05/18/22
Vaxart Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/09/22